Preview Newsletter
XARELTO Media Monitoring – Week of 7-8-16
-
Research Supports Risks Alleged In Xarelto Lawsuit Cases Consolidated Into MDL 2592
Jul 1, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the latest support offered to the ongoing cases against Janssen Pharmaceuticals and Bayer AG. Claims commonly allege that the plaintiffs were exposed to a substantially increased risk for catastrophic bleeding episodes while taking Xarelto—a new-generation anticoagulant produced and marketed by the pharmaceutical companies. In the past year, several studies have been published, which would appear to support those claims. -
Xarelto Lawsuit Cases In MDL 2592 Move Closer To Trial
Jul 3, 2016 | TheProductLawyers.com
By Banvillle Law
TheProductLawyers.com reports on progress of the multidistrict litigation (MDL) No. 2592 against Xarelto and its manufacturers—Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson.) Late in 2015, the more than 2,800 plaintiffs collectively petitioned the U.S. Judicial Panel on Multidistrict Litigation (JPML) for an order of consolidation. Allegations held in common include an undue risk of harm associated with the use of Xarelto and suggest the anticoagulant is responsible for injuries sustained. -
Xarelto Lawsuit From New Jersey Joins MDL 2592
Jul 4, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the latest lawsuit against Janssen Pharmaceuticals and Bayer AG focused on their new-generation drug, Xarelto. The plaintiff, a New Jersey man, claims that the pharmaceutical companies were negligent in their duty to warn both the public and medical professionals of the dangerous complications and side effects associated with the use of the drug. He says that after six months of using Xarelto, he suffered from a massive gastrointestinal bleed, which will require ongoing treatment. -
Xarelto Side Effects Include Uncontrollable Bleeding And Death
Jul 5, 2016 | McGartland Law Firm PLLC
By McGartland Law Firm PLLC
Xarelto (rivaroxaban) was approved by the FDA in 2011 to prevent blood clotting in patients who were recovering from knee and hip replacement surgeries. Blood clots are a common risk in post-surgical patients, and blood thinners can reduce the risks of pulmonary embolisms and strokes due to clotting. However, the blood thinners themselves also carry risks.Xarelto Increases Risk of Irreversible Bleeding and Other Life-Threatening Side Effects -
Research Linking Hemorrhages With Drug May Lend Support To Xarelto Lawsuit Plaintiff Claims
Jul 5, 2016 | TheProductLawyers.com
By Banville Law
July 05, 2016 – /PressAdvantage/ – TheProductLawyers.com announces research that could lend support to claims against Xarelto and its manufacturers, Janssen Pharmaceuticals (a division of Johnson & Johnson) and Bayer AG. An apparent link between the risk for spontaneous catastrophic bleeding and the use of the drug prompts ever-mounting concern from the public. -
Studies Lend Potential Support For Xarelto Lawsuit Claims
Jul 5, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com offers insight on scholarly studies that may lend credibility to claims against Xarelto and its manufacturers, Janssen Pharmaceuticals and Bayer AG. An apparent link between an elevated risk for catastrophic hemorrhages and the new-generation blood thinner incites concern from both the public sphere and the medical community. -
Bellwether Trials Announced In Ongoing MDL Of Xarelto Lawsuit Cases
Jul 6, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com announces additional developments in the multidistrict litigation against Xarelto and its manufacturers, Janssen Pharmaceuticals, and Bayer AG. Late last year, the U.S. Judicial Panel on Multidistrict Litigation agreed to combine more than 2,800 individual lawsuits against the drug companies on the basis of common claims and allegations. The resulting consolidation, MDL No. 2592, will ultimately be tried in the Eastern District of Louisiana under Judge Eldon Fallon. -
Xarelto Lawsuit Cases Move Forward With Bellwether Trials
Jul 6, 2016 | The ProductLawyers.com
By Banville Law
TheProductLawyers.com announces new developments in the ongoing multidistrict litigation (MDL) against Xarelto and its manufacturers, Janssen Pharmaceuticals (a subsidiary of Johnson &Johnson) and Bayer AG. Late last year, the U.S. Judicial Panel on Multidistrict Litigation combined more than 2,800 lawsuits with common allegations to form MDL No. 2592. Judge Eldon Fallon will preside over the litigation in the Eastern District of Louisiana. -
Two Bellwether Trial Dates Announced For MDL Of Xarelto Lawsuit Cases
Jul 6, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the latest developments in the lawsuits against Xarelto and the pharmaceutical companies Bayer AG and Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Late in 2015, the U.S. Judicial Panel on Multidistrict Litigation (JPML) agreed to combine more than 2,800 individual cases into a multidistrict litigation (MDL 2592) against the drug and its manufacturers on the basis of common claims. They announced that the trials for MDL 2592 would take place in the Eastern District of Louisiana, with Judge Eldon Fallon presiding. -
Over 600 Xarelto Lawsuits Filed in a Single Week
Jul 5, 2016 | Top Class Actions
By Joanna Szabo
Adding to the growing number of Xarelto lawsuits in this country, over 600 Xarelto lawsuits were filed in a single week as part of an ongoing multidistrict litigation in Louisiana federal court. -
Xarelto Side Effects Reviews
Jul 7, 2016 | Top Class Actions
By Kim Gale
Xarelto is an anticoagulant, more commonly called a blood thinner. However, serious Xarelto side effects may outweigh the benefits of the drug. -
Case Management Directives Given For MDL Of Xarelto Lawsuit Cases
Jul 7, 2016 | The Legal Examiner
By Laurence Banville
TheProductLawyers.com reports on case management orders pertaining to the multidistrict litigation (MDL) No. 2592 against the manufacturers of Xarelto. Representing nearly 3,000 individual lawsuits, the MDL was consolidated late last year by the U.S. Judicial Panel on Multidistrict Litigation (JPML). The JPML appointed Judge Eldon Fallon to preside over the MDL in the Eastern District of Louisiana. Subsequently, he has issued several case management directives intended to further streamline the process of justice.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
-
Research Supports Risks Alleged In Xarelto Lawsuit Cases Consolidated Into MDL 2592
Jul 1, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the latest support offered to the ongoing cases against Janssen Pharmaceuticals and Bayer AG. Claims commonly allege that the plaintiffs were exposed to a substantially increased risk for catastrophic bleeding episodes while taking Xarelto—a new-generation anticoagulant produced and marketed by the pharmaceutical companies. In the past year, several studies have been published, which would appear to support those claims.
In April of 2015, a study chronicling the extended medical histories of nearly 46,000 patients currently engaged in an anticoagulant regimen was published in the British Medical Journal (BMJ). Researchers noted that patients who weaned off of warfarin—a traditional anticoagulant—and replaced it with Xarelto may have a two-fold increased risk in the probability of suffering a gastrointestinal bleeding event.
In another instance, Drs. Judy Hun and John C. Hwang noticed a troubling co-occurrence of circumstances in their shared practice. Intent upon discovering the cause of vitreous hemorrhages or uncontrolled eye bleeds, they designed an empirical study. Closely observing patients ranging in age from 70 to 89—all of whom had made the progressive switch from more traditional anticoagulants to Xarelto—they noted a substantive trend. They published the complete findings of their study in the June 2015 edition of JAMA Ophthalmology, noting that, "In all cases, an acute vitreous hemorrhage occurred shortly after rivaroxaban (Xarelto) treatment was initiated."
Late last year, more than 2,800 federal cases against Xarelto and its manufacturers were consolidated into the multidistrict litigation (MDL) No. 2592. Among the plaintiffs, the common cause against Xarelto is clear in their claims. The cases allege that taking the new-generation anticoagulant substantially increased their risk of a catastrophic bleeding event. Many parties represented are seeking reparations for injury or even death as a result of these risks. Judge Eldon Fallon has been appointed to preside over the MDL in the Eastern District Court of Louisiana. It is clear that, as the cases move closer to a court date, more lawsuits are likely to be combined with the MDL.
https://www.pressadvantage.com/story/11136-research-supports-risks-alleged-in-xarelto-lawsuit-cases-consolidated-into-mdl-2592
-
Xarelto Lawsuit Cases In MDL 2592 Move Closer To Trial
Jul 3, 2016 | TheProductLawyers.com
By Banvillle Law
TheProductLawyers.com reports on progress of the multidistrict litigation (MDL) No. 2592 against Xarelto and its manufacturers—Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson.) Late in 2015, the more than 2,800 plaintiffs collectively petitioned the U.S. Judicial Panel on Multidistrict Litigation (JPML) for an order of consolidation. Allegations held in common include an undue risk of harm associated with the use of Xarelto and suggest the anticoagulant is responsible for injuries sustained.
Issuing their approval in December, the JPML cited conservation of resources for all parties and expedition of the judicial process as the foundation of its verdict. In order to avoid the confusion of multiple verdicts, they also appointed Judge Eldon Fallon to oversee MDL 2592 in the Eastern District of Louisiana. Currently, all parties are in the process of selecting bellwether cases for trial, a measure intended to further expedite the legal proceedings once the MDL cases go to court.
In 2011, the U.S. Food and Drug Administration granted Xarelto approval. The drug was intended primarily as a clot preventative in individuals recovering from hip or knee replacement surgeries as well as a treatment option for pulmonary embolism or deep vein thrombosis. Soon after, it was approved for use as a stroke preventative in individuals suffering from atrial fibrillation. Initially, both the public and medical circles hailed the new-generation anticoagulant as a miracle drug, but that attitude has largely shifted.
Many individuals claim that using Xarelto exposed them to an elevated risk of catastrophic bleeding episodes, which would necessitate drastic medical intervention. Further, they assert that the episodes caused lasting damage that either requires continued care or results in death. The plaintiffs of MDL 2592 contend that the drug companies responsible for manufacturing and distributing Xarelto are guilty of negligence because they failed to adequately warn the public and the medical community of these potential risks.
In addition to the parties represented by the MDL, a mass tort program of 550 individual suits is scheduled to appear before the Philadelphia Court of Common Pleas. The plaintiffs of MDL 2592 feel confident that, as their cases move closer to court dates, more individuals will come forward seeking justice for alleged harm.
http://www.digitaljournal.com/pr/2994123#ixzz4DkdCnBKM
-
Xarelto Lawsuit From New Jersey Joins MDL 2592
Jul 4, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the latest lawsuit against Janssen Pharmaceuticals and Bayer AG focused on their new-generation drug, Xarelto. The plaintiff, a New Jersey man, claims that the pharmaceutical companies were negligent in their duty to warn both the public and medical professionals of the dangerous complications and side effects associated with the use of the drug. He says that after six months of using Xarelto, he suffered from a massive gastrointestinal bleed, which will require ongoing treatment.
His case, filed in the federal court of the Eastern District of Louisiana in November of 2015, will join the more than 2,800 court cases that cite similar grievances. In December of 2015, after receiving a petition for consolidation, the U.S. Judicial Panel on Multidistrict Litigation (JPML) issued an order to create multidistrict litigation (MDL) 2592.
All lawsuits against the aforementioned drug companies that cite the common allegations of negligence and potential harm in connection with Xarelto will be combined, including any subsequent federal court cases that arise. Both MDL 2592 and a mass tort program of more than 550 cases—which is slated to appear before the Philadelphia Court of Common Pleas—assert that the drug posed a serious risk of injury and that the drug companies failed to warn patients or doctors adequately.
"Our lawsuits allege that the manufacturers failed to warn our clients about the severe side effects that our client's suffered from, while taking the drug", said attorney Laurence Banville, a contributor to the Xarelto litigation updates on TheProductLawyers.com. "We are speaking with families who have had brain bleeds, gastrointestinal bleeds, vaginal bleeding, and bleeding from trauma where hospitalization and extreme measures were taken by medical staff to help save the patient's life," Banville continued. "We look forward to fighting for the rights of our clients and pursuing just compensation for the injuries and hospitalization."
http://www.digitaljournal.com/pr/2994350#ixzz4DkePIn77
-
Xarelto Side Effects Include Uncontrollable Bleeding And Death
Jul 5, 2016 | McGartland Law Firm PLLC
By McGartland Law Firm PLLC
Xarelto (rivaroxaban) was approved by the FDA in 2011 to prevent blood clotting in patients who were recovering from knee and hip replacement surgeries. Blood clots are a common risk in post-surgical patients, and blood thinners can reduce the risks of pulmonary embolisms and strokes due to clotting. However, the blood thinners themselves also carry risks.Xarelto Increases Risk of Irreversible Bleeding and Other Life-Threatening Side Effects
The most worrying side effect of most anticoagulants is excessive bleeding, since the blood has been prevented from clotting. Most older blood thinners have ways to reverse the bleeding before it endangers the patient (such as administering Vitamin K to reverse the effect of warfarin). Xarelto has no known antidote for excessive bleeding, causing some patients taking the drug to suffer complications resulting from blood loss or even fatal bleeding.
Reported side effects of Xarelto include:Hemorrhaging. Xarelto can cause uncontrolled bleeding throughout the body, including bleeding in the gums, from the rectum, frequent or long-lasting nose bleeds, intestinal or abdominal bleeds, pink or brown urine, black or bloody stools, vaginal bleeding or increased menstrual bleeding, coughing up blood, and blood pooling within the tissues of the body (hematoma).Brain bleeds. Bleeding within the brain, also called cerebral hemorrhage, can be fatal if not corrected quickly. Patients who experience headaches or feel dizzy while taking Xarelto should seek medical attention immediately to rule out potential bleeds.Edema. Patients have suffered severe water retention and swelling in the ankles, feet, and legs known as peripheral edema. Swelling in the tissues of the body has also been known to place pressure on the heart and lungs, resulting in difficulty breathing or swallowing.Changes in the blood. Not only can Xarelto cause bleeding, it can affect the quality of a patient’s blood output. Some patients have suffered decreased hemoglobin production and reduced platelet levels, affecting blood clotting risks.Infections. Recent studies have shown that patients taking Xarelto after knee and hip replacements are at greater risk of healing complications. A study of over 10,000 patients discovered that Xarelto carried four times the risk of wound complications, most notably deep-tissue infections and leakage, which often required additional surgeries.Paralysis. Patients who undergo spinal injections or epidurals while taking Xarelto are at increased risk of developing a blood clot in the spine, which can lead to paralysis. Spinal clotting risks are also present for some surgical patients, especially those who regularly take NSAIDs for pain.
Although Xarelto has been linked to serious side effects, patients should always consult their doctor before discontinuing the medication. A sudden stop or decrease in the drug can cause a blood clot that could injure the patient, so it is best to discuss ways to wean off of Xarelto with a medical professional.Help for Patients and Families Injured by Xarelto
Drugmakers Bayer and Johnson & Johnson have made billions of dollars from sales of Xarelto, which continues to be one of their highest-grossing medications. However, the number of lawsuits filed against Bayer is increasing every month, many of which are requesting that the drug be removed from the market. The most common allegation against the drug’s manufacturers is that they were aware of the risks of bleeding but failed to warn the public, opting instead to hide potentially harmful clinical data. Some plaintiffs have even claimed that the drug companies identified bleeding problems in early clinical trial testing, but failed to follow these tests with more comprehensive trials before releasing the drug onto the market.
The McGartland Law Firm is asking patients and families who suffered as a result of taking Xarelto to come forward and join the lawsuit against Bayer and Johnson & Johnson. We believe that these drug manufacturers should be held responsible for causing countless injuries and deaths in the name of profit, and we will fight aggressively on your behalf to get you what you are owed. We have recovered multi-million dollar settlements for our clients, and we do not collect any legal fees unless we win your case. Call the number on this page today to speak to a member of our legal team.
http://www.mcgartland.com/library/bleeding-infections-and-other-deadly-xarelto-side-effects.cfm
-
Research Linking Hemorrhages With Drug May Lend Support To Xarelto Lawsuit Plaintiff Claims
Jul 5, 2016 | TheProductLawyers.com
By Banville Law
July 05, 2016 – /PressAdvantage/ – TheProductLawyers.com announces research that could lend support to claims against Xarelto and its manufacturers, Janssen Pharmaceuticals (a division of Johnson & Johnson) and Bayer AG. An apparent link between the risk for spontaneous catastrophic bleeding and the use of the drug prompts ever-mounting concern from the public.
The new-generation anticoagulant received FDA approval in 2011. Initially, it was warmly embraced as a breakthrough in clot prevention. Approved uses included clot prevention for those with pulmonary embolism, deep vein thrombosis, and individuals recovering from replacement surgery on knees or hips. Additionally, the drug was approved as a stroke preventative in individuals with atrial fibrillation.
Soon after, adverse event reports claiming a link between the drug and strokes, clots, massive pulmonary embolisms, and uncontrollable internal and external hemorrhages began accumulating. Doctors John C. Hwang and Judy H. Hun, having prescribed the drug to patients in their care, conducted a study of their own patients.
They noted that at least three of their patients taking Xarelto had developed “spontaneous vitreous hemorrhage” or eye bleeding. Examination of patient histories revealed that the risk for this type of bleeding was most prevalent among individuals who had switched from a more traditional blood thinner, such as warfarin, to the new anticoagulant.
Another study of the longitudinal variety drew data from patients across the United States and compared Xarelto, Pradaxa, and warfarin. Collecting patient histories from more than 46,000 individuals using anticoagulants —39,607 warfarin; 4,907 Pradaxa; 1,649 Xarelto—a trend emerged that suggested a link between dangerous risk of bleeding and the new drug. There was, it was noted, “as much as a 50 percent increase in the risk of gastrointestinal bleeding with dabigatran compared with warfarin or a twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.”
In late 2015, the U.S. Judicial Panel on Multidistrict Litigation combined more than 2,800 lawsuits with similar claims against Xarelto to form MDL No. 2592. The cases for the mass litigation will be tried in the Eastern District of Louisiana under Judge Eldon Fallon. Additional cases with similar claims will be incorporated into the MDL as the cases await trial.
http://www.wrcbtv.com/story/32378622/research-linking-hemorrhages-with-drug-may-lend-support-to-xarelto-lawsuit-plaintiff-claims
-
Studies Lend Potential Support For Xarelto Lawsuit Claims
Jul 5, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com offers insight on scholarly studies that may lend credibility to claims against Xarelto and its manufacturers, Janssen Pharmaceuticals and Bayer AG. An apparent link between an elevated risk for catastrophic hemorrhages and the new-generation blood thinner incites concern from both the public sphere and the medical community.
Granted FDA approval in 2011, Xarelto was initially embraced as a breakthrough in clot prevention treatments. Its original applications included clot prevention in those with pulmonary embolisms, deep vein thrombosis, and in patients recovering from hip and knee replacement surgeries. It was also approved to act as a stroke preventative for individuals with atrial fibrillation, a cardiac condition that increases the risk of stroke.
However, the rosy reception soon dimmed in the face of a mounting number of adverse event reports to the FDA that alleged a connection between Xarelto and strokes, clots, massive pulmonary embolisms, and uncontrollable hemorrhages. Alarmed by this potential danger, Drs. John C. Hwang and Judy H. Hun conducted a preliminary study of their own patients who were taking Xarelto at the time. They noted that at least three patients had developed "spontaneous vitreous hemorrhage," also called eye bleeding. Further, their study revealed that the potential for these adverse events seemed elevated in those who had switched to Xarelto from a more traditional anticoagulant.
Another national study was completed which compared patients taking three blood thinners. Drawing on more than 46,000 patient histories, the study compared warfarin (39,607), Pradaxa (4,907), and Xarelto (1,649). After two years, the collated data seemed to indicate a clear connection. There was, it was noted, "as much as a 50 percent increase in the risk of gastrointestinal bleeding with dabigatran compared with warfarin or a twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin."
The U.S. Judicial Panel on Multidistrict Litigation has combined more than 2,800 lawsuits alleging harm from Xarelto use. Cases in multidistrict litigation (MDL) 2592 will be tried in the Eastern District of Louisiana by Judge Eldon Fallon. As the court dates approach, additional cases against the drug are expected to be added to the mass litigation.
http://www.digitaljournal.com/pr/2996014#ixzz4DkfGD36Y
-
Bellwether Trials Announced In Ongoing MDL Of Xarelto Lawsuit Cases
Jul 6, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com announces additional developments in the multidistrict litigation against Xarelto and its manufacturers, Janssen Pharmaceuticals, and Bayer AG. Late last year, the U.S. Judicial Panel on Multidistrict Litigation agreed to combine more than 2,800 individual lawsuits against the drug companies on the basis of common claims and allegations. The resulting consolidation, MDL No. 2592, will ultimately be tried in the Eastern District of Louisiana under Judge Eldon Fallon.
However, in order to obtain a better idea of how jurors will respond to evidence and testimony, Fallon ordered that four cases be selected for bellwether trials. According to court documents, the first two have been scheduled for trial in the Eastern District of Louisiana on February 6th, 2017 and March 13th, 2017, respectively. The final two cases will be tried in as yet undisclosed locations.
The upcoming bellwether trials from those cases involved in the Xarelto MDL should provide plaintiffs, defendants and all attorneys with a more clear idea of how juries might respond to certain pieces of testimony and evidence when each individual case heads to trial in the future.
Plaintiffs involved in the MDL commonly assert that the use of Xarelto exposes individuals to a heightened risk of adverse side effects. Among these are catastrophic bleeding events, strokes, blood clots, brain hemorrhages, and gastrointestinal bleeding. They also believe that the drug manufacturers acted with reckless negligence in failing to adequately warn the public and medical communities of these risks.
"Our lawsuits allege that the manufacturers failed to warn our clients about the severe side effects that our client's suffered from, while taking the drug," said attorney Laurence Banville, a contributor to the Xarelto litigation updates on TheProductLawyers.com. "We are speaking with families who have had brain bleeds, gastrointestinal bleeds, vaginal bleeding, and bleeding from trauma where hospitalization and extreme measures were taken by medical staff to help save the patient's life," Banville continued. "We look forward to fighting for the rights of our clients and pursuing just compensation for the injuries and hospitalization."
http://www.digitaljournal.com/pr/2997399#ixzz4DkfirRgC
-
Xarelto Lawsuit Cases Move Forward With Bellwether Trials
Jul 6, 2016 | The ProductLawyers.com
By Banville Law
TheProductLawyers.com announces new developments in the ongoing multidistrict litigation (MDL) against Xarelto and its manufacturers, Janssen Pharmaceuticals (a subsidiary of Johnson &Johnson) and Bayer AG. Late last year, the U.S. Judicial Panel on Multidistrict Litigation combined more than 2,800 lawsuits with common allegations to form MDL No. 2592. Judge Eldon Fallon will preside over the litigation in the Eastern District of Louisiana.
However, in order to provide a better understanding of juror reactions to testimony and evidence, Fallon requested that four cases be selected to undergo bellwether trials. Based on information from the court, the first two trial dates have been established. They will take place in the Eastern District of Louisiana on February 6th, 2017 and March 13th, 2017, respectively. The latter two bellwether trials will be tried thereafter in courts that have yet to be specified.
Among the many plaintiffs against the pharmaceutical companies, a common claim is that the use of Xarelto exposes patients to an elevated risk of adverse side effects. Plaintiffs allege that these include brain hemorrhages, strokes, blood clots, gastrointestinal bleeding, and catastrophic bleeding events that can result in ongoing treatment needs or death. The plaintiffs also feel that both Bayer AG and Janssen Pharmaceuticals are guilty of gross negligence in their failure to adequately warn the public of these potential risks.
The panel ordered that any subsequent lawsuits brought before federal courts after the consolidation of MDL 2592 would be added to the mass litigation. Both plaintiffs and lawyers are confident that as they move toward trial, additional cases will continue to be filed.
http://www.digitaljournal.com/pr/2997501#ixzz4DkgwDBRH
-
Two Bellwether Trial Dates Announced For MDL Of Xarelto Lawsuit Cases
Jul 6, 2016 | TheProductLawyers.com
By Banville Law
TheProductLawyers.com reports on the latest developments in the lawsuits against Xarelto and the pharmaceutical companies Bayer AG and Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Late in 2015, the U.S. Judicial Panel on Multidistrict Litigation (JPML) agreed to combine more than 2,800 individual cases into a multidistrict litigation (MDL 2592) against the drug and its manufacturers on the basis of common claims. They announced that the trials for MDL 2592 would take place in the Eastern District of Louisiana, with Judge Eldon Fallon presiding.
In the interest of providing all parties with a clear idea of juror response to evidence and testimony, Fallon requested that four cases be selected from the plaintiffs for bellwether trials. According to court data, the first two of these bellwether trials will be held in the Eastern District of Louisiana on February 6th, 2017 and March 13th, 2017, respectively. The latter two trials, however, will be tried in other courts that have yet to be specified.
While Xarelto did offer some significant advancements in the treatment and prevention of blood clots, plaintiffs commonly allege that its use exposes individuals to an elevated risk of brain hemorrhages, gastrointestinal bleeding, strokes, blood clots, and catastrophic bleeding events. They also claim that the pharmaceutical companies are guilty of gross negligence because they failed to adequately warn the public and medical circles of the potential risks associated with the drug.
As a part of the consolidation effort, the JPML also announced that any subsequent lawsuits with similar claims brought before a federal court would be combined with MDL 2592. Lawyers and plaintiffs are confident that as court dates approach more cases will surface and be included in their litigation.
http://www.digitaljournal.com/pr/2997619#ixzz4DkhMLzeJ
-
Over 600 Xarelto Lawsuits Filed in a Single Week
Jul 5, 2016 | Top Class Actions
By Joanna Szabo
Adding to the growing number of Xarelto lawsuits in this country, over 600 Xarelto lawsuits were filed in a single week as part of an ongoing multidistrict litigation in Louisiana federal court.
Xarelto (rivaroxaban) is a popular blood thinner, often prescribed to treat blood clots. Blood clots can be dangerous or, in some cases, fatal, so many patients use blood thinners to prevent these kinds of blood clots.
The hundreds of new Xarelto lawsuits allege that Xarelto is linked with severe Xarelto side effects that Xarelto’s manufacturer, Janssen Pharmaceuticals, should have warned about.
One of these serious Xarelto side effects is internal bleeding, which can be damaging, life-threatening, or fatal.
Xarelto Side Effects
Plaintiffs involved in these hundreds of recent Xarelto lawsuits, as well as other lawsuits in the MDL, include a variety of Xarelto bleeding side effects.
Gastrointestinal bleeding (GI bleeding)
Rectal bleeding
Uterine bleeding
Hemorrhaging
Brain hemorrhaging
Hemarthrosis (bleeding into joint spaces)
Bloody stool
Minor bleeding (nosebleeds, heavy menstrual flow)
While these Xarelto side effects are often treatable, some plaintiffs involved in these Xarelto lawsuits have filed on behalf of loved ones who died after taking Xarelto and bleeding too excessively.
Xarelto lawsuits allege that Janssen Pharmaceuticals either knew or should have known about the severity of these sometimes fatal Xarelto side effects.
However, lawsuits allege that the company failed to adequately warn both the public and the medical community about the problems linked with their drug.
In failing to warn about these potential complications, Xarelto lawsuits allege that Janssen placed Xarelto users at risk of serious or even fatal consequences.
Xarelto Lawsuits
According to Xarelto lawsuits like the over 600 hundred filed in the week of June 20, Janssen Pharmaceuticals either knew or should have known that their drug was linked with excessive internal bleeding risks, and yet failed to adequately warn the public and the medical community about the potential for these dangerous risks.
Xarelto lawsuits allege that despite this knowledge, Janssen continued to market Xarelto as completely safe and effective and diminished and downplayed its side effects, portraying the drug as if its benefits outweighed its risks.
Filing a Xarelto lawsuit cannot take away the pain and suffering of someone who has experienced severe Xarelto side effects like internal bleeding or hemorrhaging, and cannot bring a loved one back to life.
However, a Xarelto lawsuit can at least help to compensate for the financial expenses often incurred by medical bills and lost wages.
If you or someone you love has experienced severe Xarelto side effects, you may be able to file a Xarelto side effects lawsuit.
The Xarelto Multidistrict Litigation is In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL 2592, in the U.S. District Court for the Eastern District of Louisiana.
https://topclassactions.com/lawsuit-settlements/prescription/338811-600-xarelto-lawsuits-filed-single-week/
-
Jul 7, 2016 | Top Class Actions
By Kim Gale
Xarelto is an anticoagulant, more commonly called a blood thinner. However, serious Xarelto side effects may outweigh the benefits of the drug.
Xarelto may also be used by patients with atrial fibrillation (a heart rhythm disorder) to decrease the risk of stroke from a blood clot. Xarelto is also used to treat deep vein thrombosis, which can lead to blood clots in the lungs, known as pulmonary embolisms.
Xarelto is manufactured by Bayer and is known generically as rivaroxaban.
Xarelto Side Effects
The most common Xarelto side effects are muscle pain, itching or pain in the arms or legs.
Some patients could be allergic to Xarelto. Signs of an allergic reaction include hives, difficulty breathing and swelling of the face, lips, tongue or throat.
Among other Xarelto problems is that a very serious blood clot can form around the spinal cord if a patient undergoes a spinal tap or receives spinal anesthesia (epidural). This type of blood clot could cause long-term paralysis, and may be more likely to occur if the patient has:a genetic spinal defect;a spinal catheter in place;a history of spinal surgery or repeated spinal taps;recently had a spinal tap or epidural anesthesia;taken an NSAID – Advil, Aleve, Motrin, and others; ortaken other medicines to treat or prevent blood clots.
Internal Bleeding Issues
Xarelto belongs to a new breed of anticoagulants that provide uniform doses for everyone, however some patients tolerate it better than others. Internal bleeding is a possible Xarelto side effect, and can range from minor bleeding to fatality.
The FDA has issued two black box warnings because of Xarelto side effects. A black box warning is a step taken before a drug is pulled off the market.
Most alarming of all Xarelto side effects is, if someone is bleeding out, there is no antidote for Xarelto. As of now, there are no instructions for ER physicians to control bleeding induced by the drug’s blood thinning properties, which has led to thousands of Xarelto lawsuits.
The FDA warns that medical help should be sought immediately at any of these signs of bleeding:unexpected bleeding or bleeding that lasts a long time, such as nose bleeds that happen often, unusual bleeding from the gums or menstrual bleeding that is heavier than normal or vaginal bleedingbleeding that is severe or you cannot controlred, pink or brown urinebright red or black stools (looks like tar)cough up bloodvomit blood or your vomit looks like “coffee grounds”headaches, feeling dizzy or weak
Uncontrolled high blood or an ulcer can also make a person more susceptible to internal bleeding.
Xarelto Side Effect: Poor Wound Healing
In addition to bleeding complications, Xarelto lawsuits also allege the drug interferes with wound healing.
The Journal of Bone and Joint Surgery came out with a study in 2012 that said researchers looked at more than 13,000 patients who had knee or hip surgery who took either Xarelto or Heparin. The patients who had taken Xarelto had almost four times the risk of wound complications, including infections and leakage.
Surgeons reported that those with complications who had taken Xarelto sometimes ended up needing implants removed because of poor wound healing. Others had to stay on antibiotics for weeks or even months to get rid of terrible infections.
Xarelto Problems
If you or someone you love has taken Xarelto and experienced poor wound healing, internal bleeding, spinal blood clots or other Xarelto side effects, you could benefit from a class action lawsuit.
https://topclassactions.com/lawsuit-settlements/lawsuit-news/339300-xarelto-side-effects-reviews/
-
Case Management Directives Given For MDL Of Xarelto Lawsuit Cases
Jul 7, 2016 | The Legal Examiner
By Laurence Banville
TheProductLawyers.com reports on case management orders pertaining to the multidistrict litigation (MDL) No. 2592 against the manufacturers of Xarelto. Representing nearly 3,000 individual lawsuits, the MDL was consolidated late last year by the U.S. Judicial Panel on Multidistrict Litigation (JPML). The JPML appointed Judge Eldon Fallon to preside over the MDL in the Eastern District of Louisiana. Subsequently, he has issued several case management directives intended to further streamline the process of justice.
Forming The Bellwether Pool
On November 20, 2015, Fallon directed both parties to select ten cases from the 2,800 plaintiffs represented. These would be joined by twenty cases selected on the part of the court, forming a bellwether trial pool. From these lawsuits, which conformed to specific, established criteria delineated in a subsequent case management order, a total of four suits would be selected for trial by jury.
About Xarelto
The U.S. Food and Drug Administration (FDA) passed approval of Xarelto in July of 2011. Intended as a clot preventative for individuals with deep vein thrombosis and pulmonary embolism as well as in those recovering from hip or knee replacement surgery, the drug was hailed as a breakthrough in anticoagulant medication. However, plaintiffs in MDL 2592 and the 550 cases represented in a mass tort program consolidated by the Philadelphia Court of Common Pleas allege that there are serious side effects. They further claim that use of the drug places individuals at serious risk of catastrophic bleeding events, with the potential for long-term injury and even death.
Lawsuits Allege Negligence
Plaintiffs represented in MDL 2592 state that they feel the manufacturers of Xarelto—Bayer AG and Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson—are guilty of negligent, reckless behavior. The plaintiffs in most of the lawsuits claim that the manufacturers failed to adequately warn the public of potential risks associated with the use of Xarelto.
As those involved in MDL 2592 await news of a trial date, they are confident that additional cases with similar allegations will continue to be added to their numbers.
http://newyorkcity.legalexaminer.com/fda-prescription-drugs/case-management-directives-given-for-mdl-of-xarelto-lawsuit-cases/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
Add recipients
Suggested